Iovance Biotherapeutics Q3 net loss narrows 76% year over year to $22.27 million
Bitget2026/11/05 12:12- Iovance Biotherapeutics’ third-quarter 2026 net loss narrowed 76% year over year to $22.27 million.
- Revenue climbed 80% year over year to $121.47 million.
- A supplemental approval application for lifileucel in non-squamous metastatic non-small-cell lung cancer is planned for 2027.
- Full-year 2026 revenue guidance remains $410 million to $420 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
UBS CEO warns: A Democratic sweep could slow down AI capacity building, valuation concerns are "very important"
UBS CEO Ermotti stated that the U.S. midterm elections may slow down AI capacity building and that the valuations are questionable; he also warned of persistent inflation and the risk of contagion in the European bond market.
Crypto prices
More
